This article is more than 5 years old. Information may no longer be current.

Integra LifeSciences acquires multiple product lines from Metasurg

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Integra LifeSciences recently announced the acquisition of biologics and foot and ankle product offerings from Metasurg.

The transactions, which closed in December, will allow Integra distribution rights to the entire line of foot and ankle implant solutions from Metasurg. Integra will also be able to distribute Metasurg’s amniotic product line of Biofix Regenerative Biologics, a biologic allograft derived from human placental tissue. This will add to the product line wound care offerings for the company.

Integra expects minimal long-term financial impact as a result of the acquisition, with slower growth during the transition period prior to a return to double-digit growth over the long term, according to a company release.

Reference: www.integralife.com.